These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16629421)

  • 1. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study.
    Miller DM; Cohen JA; Kooijmans M; Tsao E; Cutter G; Baier M
    Mult Scler; 2006 Apr; 12(2):180-6. PubMed ID: 16629421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.
    Ozakbas S; Cagiran I; Ormeci B; Idiman E
    J Neurol Sci; 2004 Mar; 218(1-2):3-7. PubMed ID: 14759626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis.
    Baier ML; Cutter GR; Rudick RA; Miller D; Cohen JA; Weinstock-Guttman B; Mass M; Balcer LJ
    Neurology; 2005 Mar; 64(6):992-5. PubMed ID: 15781814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity and reliability of the MSQLI in cognitively impaired patients with multiple sclerosis.
    Marrie RA; Miller DM; Chelune GJ; Cohen JA
    Mult Scler; 2003 Dec; 9(6):621-6. PubMed ID: 14664477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial.
    Robinson D; Zhao N; Gathany T; Kim LL; Cella D; Revicki D
    Curr Med Res Opin; 2009 May; 25(5):1121-30. PubMed ID: 19317608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life.
    Miller DM; Rudick RA; Cutter G; Baier M; Fischer JS
    Arch Neurol; 2000 Sep; 57(9):1319-24. PubMed ID: 10987899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with health-related quality of life in multiple sclerosis.
    Hopman WM; Coo H; Edgar CM; McBride EV; Day AG; Brunet DG
    Can J Neurol Sci; 2007 May; 34(2):160-6. PubMed ID: 17598592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments in the assessment of quality of life in multiple sclerosis (MS).
    Fischer JS; LaRocca NG; Miller DM; Ritvo PG; Andrews H; Paty D
    Mult Scler; 1999 Aug; 5(4):251-9. PubMed ID: 10467384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.
    Miller DM; Weinstock-Guttman B; Bourdette D; You X; Foulds P; Rudick RA
    Mult Scler; 2011 Jun; 17(6):734-42. PubMed ID: 21300736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability and validity of the multiple sclerosis quality of life inventory in older individuals.
    Dilorenzo T; Halper J; Picone MA
    Disabil Rehabil; 2003 Aug; 25(16):891-7. PubMed ID: 12857582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a pulsed electromagnetic therapy on multiple sclerosis fatigue and quality of life: a double-blind, placebo controlled trial.
    Lappin MS; Lawrie FW; Richards TL; Kramer ED
    Altern Ther Health Med; 2003; 9(4):38-48. PubMed ID: 12868251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in patients with longstanding 'benign multiple sclerosis'.
    Bueno AM; Sayao AL; Yousefi M; Devonshire V; Traboulsee A; Tremlett H
    Mult Scler Relat Disord; 2015 Jan; 4(1):31-8. PubMed ID: 25787050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Dec; 32(12):1969-1974. PubMed ID: 27603119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.
    Hobart J; Kalkers N; Barkhof F; Uitdehaag B; Polman C; Thompson A
    Mult Scler; 2004 Feb; 10(1):41-6. PubMed ID: 14760951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two Multiple Sclerosis Quality-of-Life Measures: Comparison in a National Sample.
    Moore F; Vickrey B; Fortin K; Lee L
    Can J Neurol Sci; 2015 Jan; 42(1):55-63. PubMed ID: 25586701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Sclerosis Impact Scale (MSIS-29): relation to established measures of impairment and disability.
    Hoogervorst EL; Zwemmer JN; Jelles B; Polman CH; Uitdehaag BM
    Mult Scler; 2004 Oct; 10(5):569-74. PubMed ID: 15471375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A study validating changes in the multiple sclerosis functional composite.
    Hoogervorst EL; Kalkers NF; Uitdehaag BM; Polman CH
    Arch Neurol; 2002 Jan; 59(1):113-6. PubMed ID: 11790238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.